Login to Your Account

Savient Terminates Phase II Prosaptide Analgesia Study

By Karen Pihl-Carey

Monday, March 14, 2005
Savient Pharmaceuticals Inc. has halted its Phase II trial for Prosaptide after an interim analysis indicated the product would not reach its analgesia efficacy endpoint. (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription